Armata Pharmaceuticals Announces That CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting
Armata Pharmaceuticals Announces That CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for LOS ANGELES, Nov. 19, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Dr. Deborah Birx, Chief Executive Officer, will deliver a presentation at 1:15pm ET at the 5th Annual Phage Futures Annual Meeting, which is being held November 19th in Boston, MA.
洛杉磯，2024年11月19日 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (紐交所美國: ARMP) （"Armata"或"公司"），是一家專注於針對抗生素耐藥和難治性細菌感染的病原特異性噬菌體治療的臨床階段生物技術公司，今天宣佈首席執行官德博拉·比爾克斯博士將於東部時間下午1:15在第5屆噬菌體期貨年會上發表演講，該會議於11月19日在馬薩諸塞州波士頓舉行。
For more information:
了解更多信息：
About Armata Pharmaceuticals, Inc.
關於Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.
Armata是一家專注於利用其專有的噬菌體技術開發針對抗生素耐藥和難治性細菌感染的病原特異性噬菌體治療藥物的臨床階段生物技術公司。Armata正在開發和推進一系列天然和合成噬菌體候選藥物，其中包括綠膿桿菌、金黃色葡萄球菌和其他病原體的臨床候選藥物。Armata致力於利用從實驗室到臨床的藥物開發專業知識推動噬菌體療法，包括內部研發噬菌體特異性cGMP製造。
Media Contacts:
媒體聯繫方式:
At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
[email protected]
310-665-2928 x234
在Armata：
Pierre Kyme
Armata製藥公司
[email protected]
310-665-2928 x234
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
[email protected]
212-915-2569
投資者關係:
喬伊斯·阿萊爾
LifeSci Advisors, LLC
[email protected]
212-915-2569
SOURCE Armata Pharmaceuticals, Inc.
來源：Armata Pharmaceuticals，Inc.
